A Phase II Trial of Cabozantinib (XL184) in Patients With Castrate-Resistant Prostate Cancer Metastatic to Bone.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 29 Apr 2016 Status changed from active, no longer recruiting to discontinued.
- 15 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.